HALOZYME THERAPEUTICS INC (HALO) Forecast, Price Target & Analyst Ratings
NASDAQ:HALO • US40637H1095
67.64 USD
-0.5 (-0.73%)
Last: Mar 10, 2026, 12:31 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for HALOZYME THERAPEUTICS INC (HALO).
Forecast Snapshot
Consensus Price Target
$86.19
+ 27.42% Upside
Next Earnings Forecast
Release DateMay 4, 2026
PeriodQ1 / 2026
EPS Estimate$1.56
Revenue Estimate364.76M
ChartMill Buy Consensus
76.00%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$86.19
Upside
+ 27.42%
From current price of $67.64 to mean target of $86.19, Based on 15 analyst forecasts
Low
$56.56
Median
$91.80
High
$100.80
Price Target Revisions
1 Month
8.33%
3 Months
11.18%
Price Target Summary
15 Wall Street analysts provided a forecast for the next 12 months for HALO. The average price target is 86.19 USD. This implies a price increase of 27.42% is expected in the next year compared to the current price of 67.64.
The average price target has been revised upward by 11.18% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
76.00%
HALO was analyzed by 15 analysts. The buy percentage consensus is at 76. So analysts seem to be have mildly positive about HALO.
In the previous month the buy percentage consensus was at a similar level.
HALO was analyzed by 15 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-19 | Benchmark | Maintains | Buy -> Buy |
| 2026-02-19 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2026-01-08 | TD Cowen | Maintains | Buy -> Buy |
| 2025-12-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-11-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-11-18 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2025-11-04 | Citizens | Maintains | Market Outperform -> Market Outperform |
| 2025-10-27 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-10-20 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-10-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-10-14 | Leerink Partners | Upgrade | Underperform -> Market Perform |
| 2025-10-02 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-09-24 | Benchmark | Maintains | Buy -> Buy |
| 2025-09-22 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-08-18 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-08-07 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-08-06 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-08-06 | Morgan Stanley | Upgrade | Equal-Weight -> Overweight |
| 2025-08-06 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-07-16 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-05-29 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-05-14 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2025-05-13 | Leerink Partners | Downgrade | Market Perform -> Underperform |
| 2025-05-07 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-04-25 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMay 4, 2026
PeriodQ1 / 2026
EPS Estimate$1.56
Revenue Estimate364.76M
Revenue Q2Q37.72%
EPS Q2Q40.41%
Number of Analysts9
Next Earnings Revisions
Revenue (1 Month)
-2.16%
Revenue (3 Months)
-5.22%
EPS (1 Month)
-13.18%
EPS (3 Months)
-15.58%
Next Earnings Summary
HALO is expected to report earnings on 5/4/2026. The consensus EPS estimate for the next earnings is 1.56 USD and the consensus revenue estimate is 364.76M USD.
The next earnings revenue estimate has been revised downward by 5.22% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 829.253M 25.63% | 1.015B 22.44% | 1.397B 37.55% | 1.791B 28.24% | 2.02B 12.79% | 2.185B 8.17% | 1.96B -10.30% | 1.813B -7.50% | 1.727B -4.74% | 1.487B -13.90% | 1.361B -8.47% | |
| EBITDA YoY % growth | 424.93M 25.35% | 632.787M 48.92% | 904.344M 42.91% | 1.197B 32.36% | 1.444B 20.63% | 1.586B 9.83% | 1.502B -5.30% | 1.322B -11.98% | 1.321B -0.08% | 1.137B -13.93% | 875.98M -22.96% | |
| EBIT YoY % growth | 340.074M 17.51% | 551.475M 62.16% | 816.293M 48.02% | 1.094B 34.02% | 1.333B 21.85% | 1.459B 9.45% | 1.244B -14.74% | 1.097B -11.82% | 1.008B -8.11% | 770.2M -23.59% | 646.83M -16.02% | |
| Operating Margin | 41.01% | 54.32% | 58.45% | 61.08% | 65.99% | 66.77% | 63.47% | 60.51% | 58.37% | 51.80% | 47.53% | |
| EPS YoY % growth | 2.78 25.23% | 4.23 52.16% | 4.13 -2.36% | 8.18 97.97% | 10.04 22.85% | 10.54 4.94% | 9.72 -7.78% | 8.78 -9.71% | 8.24 -6.16% | 6.57 -20.19% | 5.75 -12.49% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | 1.56 40.41% | 1.84 19.49% | 2.07 20.38% | 2.07 960.63% |
| Revenue Q2Q % growth | 364.76M 37.72% | 405.6M 24.52% | 438.43M 23.76% | 448.88M -0.64% |
| EBITDA Q2Q % growth | 227.08M 40.19% | 258.78M 6.32% | 344.78M 23.45% | 381.18M 11.31% |
| EBIT Q2Q % growth | 206.76M 46.08% | 240.92M 19.01% | 288.76M 32.51% | 304.76M 19.80% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
36.66%
EPS Next 5 Year
16.27%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
15.64%
Revenue Next 5 Year
5.11%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
22.40%
EBIT Next 5 Year
8.86%
HALOZYME THERAPEUTICS INC / HALO Forecast FAQ
Can you provide the average price target for HALOZYME THERAPEUTICS INC stock?
15 analysts have analysed HALO and the average price target is 86.19 USD. This implies a price increase of 27.42% is expected in the next year compared to the current price of 67.64.
Can you provide the upcoming earnings date for HALOZYME THERAPEUTICS INC?
HALOZYME THERAPEUTICS INC (HALO) will report earnings on 2026-05-04.
Can you provide the consensus estimates for HALOZYME THERAPEUTICS INC next earnings?
The consensus EPS estimate for the next earnings of HALOZYME THERAPEUTICS INC (HALO) is 1.56 USD and the consensus revenue estimate is 364.76M USD.
What is the expected long term growth rate for HALO stock?
The expected long term growth rate for HALOZYME THERAPEUTICS INC (HALO) is 15.64%.